Gan & Lee Pharmaceuticals (SHA: 603087) announced that China’s National Medical Products Administration (NMPA) has approved clinical trials for GLR2037, a Category 1 chemical drug and first‑in‑class androgen receptor proteolysis‑targeting chimera (AR PROTAC). The novel therapeutic is under development for advanced prostate cancer, with no similar product approved globally—positioning Gan & Lee as a pioneer in targeted protein degradation for oncology.
Regulatory Milestone
Item
Detail
Company
Gan & Lee Pharmaceuticals (SHA: 603087)
Product
GLR2037
Drug Class
Category 1 innovative chemical drug; AR PROTAC
Mechanism
Androgen receptor proteolysis‑targeting chimera (targeted protein degradation)
Regulatory Action
NMPA clinical trial approval
Indication
Advanced prostate cancer
Global Status
No similar product approved worldwide
PROTAC Technology – AR Degradation
Component
Function
E3 Ligase Ligand
Recruits cellular ubiquitin‑proteasome machinery
AR Ligand
Binds to androgen receptor with high affinity
Linker
Connects E3 ligase and AR ligand components
Mechanism of Action
Brings E3 ligase into proximity with AR → ubiquitination → proteasomal degradation
Therapeutic Advantage
Complete AR elimination vs. AR inhibition (enzalutamide, abiraterone); potential efficacy against resistance mutations
Strategic Implications
First‑in‑Class PROTAC: GLR2037 is the world’s first AR‑targeting PROTAC to enter clinical development, establishing Gan & Lee as a leader in targeted protein degradation—a transformative drug modality beyond small‑molecule inhibition.
Prostate Cancer Resistance: Current AR inhibitors (enzalutamide, abiraterone) face resistance via AR mutations and amplification; PROTAC‑mediated AR degradation may overcome these mechanisms and extend treatment duration.
China Innovation Leadership:Category 1 status and NMPA approval demonstrate China’s maturing capabilities in novel modality drug discovery, moving beyond biosimilars and fast‑follow inhibitors.
Global Potential: As the first AR PROTAC, GLR2037 attracts significant partnership interest from multinational pharma seeking to expand oncology pipelines with differentiated mechanisms.
Market Context
Factor
Impact
Prostate Cancer Market
~ $15 billion globally; metastatic castration‑resistant prostate cancer (mCRPC) represents high‑unmet‑need segment with limited options post‑AR inhibitor progression
PROTAC Market Evolution
Arvinas’ ARV‑471 (ER PROTAC) in Phase III; no AR‑targeting PROTACs in clinic until GLR2037; validates PROTAC modality in oncology
Known for insulin and diabetes products; GLR2037 represents strategic expansion into oncology innovation
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase I initiation, proof‑of‑mechanism validation, and partnership potential for GLR2037. Actual results may differ due to risks including first‑in‑human safety signals, PROTAC pharmacokinetic challenges, and competitive AR‑targeting program advancements.-Fineline Info & Tech
By Fineline Cube